An evidence-based systematic review on medical therapies for inflammatory bowel disease (Q37862584)

24 August 2017

1 reference

title

An evidence-based systematic review on medical therapies for inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

24 August 2017

0 references

0 references

1 reference

William Jeffery Sandborn

series ordinal

8

object named as

William J Sandborn

1 reference

24 August 2017

10

Paul Moayyedi

1 reference

24 August 2017

4

Charles N Bernstein

1 reference

24 August 2017

6

Stephen B Hanauer

1 reference

24 August 2017

1

Nicholas J Talley

1 reference

24 August 2017

3

Jean-Paul Achkar

1 reference

24 August 2017

2

Maria T Abreu

1 reference

24 August 2017

7

Sunanda V Kane

1 reference

24 August 2017

9

Thomas A Ullman

1 reference

24 August 2017

Marla C Dubinsky

5

1 reference

PubMed ID

21472012

24 August 2017

American College of Gastroenterology IBD Task Force

series ordinal

11

1 reference

PubMed ID

21472012

24 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

The American Journal of Gastroenterology

24 August 2017

1 reference

24 August 2017

106 Suppl 1

1 reference

24 August 2017

S2-25; quiz S26

1 reference

Inflammatory bowel disease

24 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Influence of inflammatory bowel disease on different dimensions of quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Hospitalization for inflammatory bowel disease in the United States between 1970 and 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Management of Crohn's disease in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Incidence of inflammatory bowel disease in the French West Indies (1997-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Clinical epidemiology of inflammatory bowel disease in Lebanon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Inflammatory bowel disease: incidence, prevalence, and disease characteristics in Barbados, West Indies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The epidemiology of inflammatory bowel disease in Canada: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Basic epidemiology of inflammatory bowel disease in Puerto Rico.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Crohn's disease in Tuzla region of Bosnia and Herzegovina: a 12-year study (1995-2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Crohn's disease incidence evolution in North-western Greece is not associated with alteration of NOD2/CARD15 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Selection criteria for preoperative endoscopic retrograde cholangiopancreatography before laparoscopic cholecystectomy and endoscopic treatment of bile duct stones: results of a retrospective, single center study between 1996-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Crohn's disease in Stockholm County during 1990-2001: an epidemiological update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Risk factors for inflammatory bowel disease in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

An update on the epidemiology of inflammatory bowel disease in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Crohn's disease in mainland China: a systematic analysis of 50 years of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Epidemiological features of ulcerative colitis in Trakya, Turkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Incidence and prevalence of ulcerative colitis in Punjab, North India

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Ulcerative colitis in Oman. A prospective study of the incidence and disease pattern from 1987 to 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The incidence of Crohn's disease in Cardiff over the last 75 years: an update for 1996-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Smoking and inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Passive smoking and inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A population-based case control study of potential risk factors for IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The risk of developing Crohn's disease after an appendectomy: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Interactions between commensal intestinal bacteria and the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A human gut microbial gene catalogue established by metagenomic sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A review of associations between Crohn's disease and consumption of sugars

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Diet as a risk factor for the development of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Hay fever, hygiene, and household size

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The increasing prevalence of Crohn's disease in industrialized societies: the price of progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Population-based cases control study of inflammatory bowel disease risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000-2004: A prospective population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

An evidence-based position statement on the management of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

How strong is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Drug insight: aminosalicylates for the treatment of IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

An experiment to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Olsalazine in maintenance of clinical remission in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Optimum dose of olsalazine for maintaining remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Discovery of the wonder drug: from cows to cortisone. The effects of the adrenal cortical hormone 17-hydroxy-11-dehydrocorticosterone (Compound E) on the acute phase of rheumatic fever; preliminary report. Mayo Clin Proc 1949;24:277-97.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Cortisone in ulcerative colitis; preliminary report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Review article: appropriate use of corticosteroids in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Budesonide for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Effects of glucocorticoids on gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Oral fluticasone propionate in active distal ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Review article: monitoring of immunomodulators in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Changes in liver biochemistry during methotrexate use for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A controlled double blind study of azathioprine in the management of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Controlled trial of azathioprine in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A controlled trial of azathioprine in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

From IFN to TNF: a journey into realms of lore

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Serious adverse events with infliximab: analysis of spontaneously reported adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Adalimumab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Biological therapies for inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The role of microbes in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Crohn's disease: the cold chain hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Double blind, placebo controlled trial of metronidazole in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Preliminary study of ciprofloxacin in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Tailoring the length of antiviral treatment for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

The natural history of adult Crohn's disease in population-based cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.58

21 January 2018

Identifiers

DOI

10.1038/AJG.2011.58

1 reference

24 August 2017

1 reference

PubMed ID

21472012